


10/528029

1/20


Figure 1



BEST AVAILABLE COPY

2/20

Figure 2



3/20

Figure 3


	EphB4 antibody	EphB4 antibody
	H-200 (Santa Cruz	H-200 (Santa Cruz
	Biotechnology)	Biotechnology)
Control	Lot # B141	Lot # F182

SW620

SW480




Figure 4




5/20

Figure 5




6/20

Figure 6




7/20

Figure 7




8/20

Figure 8




9/20

Figure 9



10/20

Figure 10



11/20

Figure 11


201 TVNLTRFPETVPREL VVPVAGSCVVD AV PAPGPSPLYCREDGQWAEQPVTGCS 254
TVNLTRFPETVPREL VVPVAGSCVV (SEQ ID NO:2- Peptide 1)
GSCVVD AV PAPGPSPLYCREDGQW (SEQ ID NO:3- Peptide 2)
EDGQWAEQPVTGCS-

255 CAPGFEEAAEGNTKCRACAQGTFKPLSGEGSCQPCPANSHTIGSAVCQCRVGY 308
CAPGFEEAEGN (SEQ ID NO:4- Peptide 3)
AAEGNTKCRACAQGTFKPLSGEGSC (SEQ ID NO:5- Peptide 4)
GEGSCQPCPANSHTIGSAVCQCR (SEQ ID NO: 6-
Peptide 5)
VCQCRVGY-

309 FRARTDPRGAPCTTPPSAPRSVVSRLNGSSLHLEWSAPLES GGREDLT YALRCR 362
FRARTDPRGAPCTTPPS (SEQ ID NO:7- Peptide 6)


12/20

Figure 12




13/20

Figure 13




14/20

Figure 14



15/20

Figure 15



16/20

Figure 16

201 TVNLTRFPETVPRELVVPVAGSCVVDVAVPAPGPSPLYCREDGQWAEQPVTGCS 254

TVNLTRFPETVPRELVVPVAGSCVV (SEQ ID NO:2- Peptide 1)

GSCVVD A V P A P G P S P S L Y C R E D G Q W (SEQ ID NO:3- Peptide 2)


AGSCVVDA (SEQ ID NO:8- Peptide 7)

VAGSCVVDAAV (SEQ ID NO:9-Peptide 8)

LVVPVAGSCVVDAVPA (SEQ ID NO:10- Peptide 9)

17/20

Figure 17



18/20

Figure 18


SEQ ID NO:1

Homo Sapiens Ephrin type-B receptor 4 Precursor (EphB4)

1	MELRVLLCWA	SLAAALEETL	LNTKLETADL	KWVTFPQVDG	WEELSGLDE	EQHSVRTYEV
61	CDVQRAPGQA	HWLRTGWVPR	RGAVHVIYATL	RFTMLECLSL	PRAGRCKET	FTVFYYESDA
21	DTATALTPAW	MENPYIKVDT	VAAEHLTRKR	PGAEATGKVN	VKTLRLGPLS	KAGFYLAQD
181	QGACMALLSL	HLFYKKCAQL	TVNLTRFPET	VPRELVPVA	GSCVVDAVPA	PGPSPSLYCR
241	EDGQWAEQPV	TGCSCAPGFE	AAEGNTKCRA	CAQGTFKPLS	GEGSCQPCPA	NSHSNTIGSA
301	VCQCRVGYFR	ARTDPRGAPC	TTPPSAPRSV	VSRLNGSSLH	LEWSAPLESG	GREDLTYALR
361	CRECRPGGSC	APCGGDLTFD	PGPRDLVEPW	VVVRGLRPDF	TYTFEVTALN	GVSSLATGPV
421	PFEPVNVTTD	REVPPAVSDI	RVTRSSPSSL	SLAWAVPRAP	SGAVLDYEVK	HEKGAEGPS
481	SVRFLKTSN	RAELRGLKRG	ASYLVQVRAR	SEAGYGPFQ	EHHSQTQLDE	SEGWREQLAL
541	IAGTAVVGVV	LVLVVIVVAV	LCLRKQSNR	EAESDKHGQ	YLIGHGTKVY	IDPFTYEDPN
601	EAVREFAKEI	DVSIVKIEEV	IGAGEFGEVC	RGRLKAPGKK	ESCVAIKTLK	GGYTERQRRE
661	FLSEASIMGQ	FEHPNIIRLE	GVVTNSMPVM	ILTEFMENGA	LDSFLRLNDG	QFTVIQLVGM
721	LRGIASGMRY	LAEMSYVHRD	LAARNILVNS	NLVCKVSDFG	LSRFLEENSS	DPTYTSSLGG
781	KIPRWTAPE	AIAFRKFTSA	SDAWSYGIVM	WEVMSFGERP	YWDMSNQDVI	NAIEQDYRLP
841	PPDCPTSLH	QLMLDCWQKD	RNARPRFPQV	VSALDKMIRN	PASLKIVARE	GGASHPLLD
901	QRQPHYSAFG	SVGEWLRAIK	MGRYEESFAA	AGFGSFELVS	QISAEDLLRI	GVTLAGHQKK
961	ILASVQHMK	QAKPGTPGGT	GGPAPQY			

19/20


Figure 19




20/20

Figure 20

201 TVNLTRFPETVPRELVVPVAGSCVVD AVPAPGPSPSLYCREDGQWAEQPVTGCS 254
AGSCVVDAVPAPGPSPSLYCREDGQ (Peptide 11, SEQ IDNO:12)
|
AGSCVVNAVAPGPSPSLYCREDGQ (Peptide 10, SEQ ID NO:11)



Aspartate (D)



Asparagine (N)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.